| Literature DB >> 26754943 |
Matteo Valzano1, Valentina Cecarini2, Alessia Cappelli3, Aida Capone4, Jovana Bozic5, Massimiliano Cuccioloni6, Sara Epis7, Dezemona Petrelli8, Mauro Angeletti9, Anna Maria Eleuteri10, Guido Favia11, Irene Ricci12.
Abstract
BACKGROUND: Malaria control strategies are focusing on new approaches, such as the symbiotic control, which consists in the use of microbial symbionts to prevent parasite development in the mosquito gut and to block the transmission of the infection to humans. Several microbes, bacteria and fungi, have been proposed for malaria or other mosquito-borne diseases control strategies. Among these, the yeast Wickerhamomyces anomalus has been recently isolated from the gut of Anopheles mosquitoes, where it releases a natural antimicrobial toxin. Interestingly, many environmental strains of W. anomalus exert a wide anti-bacterial/fungal activity and some of these 'killer' yeasts are already used in industrial applications as food and feed bio-preservation agents. Since a few studies showed that W. anomalus killer strains have antimicrobial effects also against protozoan parasites, the possible anti-plasmodial activity of the yeast was investigated.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26754943 PMCID: PMC4709964 DOI: 10.1186/s12936-015-1059-7
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Fig. 1Anion-exchange chromatography profile. Profile obtained through the anion-exchange chromatography (DEAE) performed on the concentrated supernatant of the strain WaF1712. The same elution profile was achieved also for the strains WaATCC 96603 (positive control) and WaUM3 (negative control)
Fig. 2In vitro anti-plasmodial activity of WaKTs against Plasmodium berghei sporogonic stages. The development of sporogonic stages showed inhibition rates of 87.5 and 92.3 % when they were incubated with 100 µg/ml of WaF17.12 and WaATCC 96603 KTs, respectively, for 24 h at 19 °C. The histogram reports the average numbers of the sporogonic stages obtained from the cell count of three wells for each treatment and control (LC50 values were 61.3 and 64.6 µg/ml for WaATCC 96603 and WaF17.12, respectively). The One Way ANOVA Bonferroni’s Multiple Comparison tests were used to perform the statistical analysis. Statistical significance is expressed as a p value. ***p < 0.001
Fig. 3Inhibition percentages of Plasmodium berghei sporogonic stages development at different KTs concentration. The KTs of WaF17.12 and WaATCC 96603 showed a dose-dependent activity at the tested concentrations of 100, 75, 60 and 25 µg/ml. Inhibition percentages upon exposure to 25, 60, 75 µg/ml of WaF17.12 KT were approximately of 17, 43, 66 %, whereas for WaATCC 96603 KT were about 16, 48 and 70 %
Fig. 4Fluorescence microscopy evaluation of GFP-transfected parasites. Different stages of untreated parasite development are shown in a–c (a zygote; b elongated zygote; c mature ookinete). e and g show faint fluorescent signals into zygotes (indicated by white arrows) treated with WaF17.12-KT. In d and f phase-contrasts (the zygotes are indicated by white arrows) are shown. All the parasites were observed using a ×100 objective. In a–c scale bar 10 μm whereas in d–g scale bar 20 μm
Fig. 5Images of Plasmodium berghei cultures in Giemsa-stained smears. Parasites sporogonic stages, both controls (a–c) and treated with 100 µg/ml of WaF17.12 KT (d–f) were stained with Giemsa and analysed under light microscope (×100 objective). See text for details. Scale bar 10 μm
Effects of castanospermine on KTs activity against P. berghei
| Pretreatment | Treatment | Average number of sporogonic stages/well |
|---|---|---|
| β-Glucanase inhibitor (25 μM) | KTs (100 μg/ml) | |
| None | None | 305 ± 22.7 |
| None |
| 62 ± 11.5 |
| None |
| 35 ± 4.6 |
| Castanospermine |
| 125 ± 8.1 |
| Castanospermine |
| 151 ± 4.5 |